Salinomycin effectively eliminates cancer stem-like cells and obviates hepatic metastasis in uveal melanoma

Jingfeng Zhou, Shenglan Liu, Yun Wang, Wei Dai, Hailin Zou, Shubo Wang, Jing Zhang, Jingxuan PanMolecular 2019 · DOI

TL;DR

This study investigates the potential of salinomycin, an existing agricultural antibiotic, as a novel treatment for uveal melanoma (UM), a rare but aggressive eye cancer that frequently metastasizes to the liver. The research demonstrates that salinomycin effectively targets and eliminates cancer stem-like cells (CSCs) in UM, a key driver of metastasis, and significantly reduces tumor growth and spread in preclinical models.

What Problem Does This Paper Address?

Uveal melanoma (UM) is the most common primary intraocular tumor, and unfortunately, liver metastasis is a major cause of mortality for patients. Current treatments for localized UM exist, but once metastasis occurs, therapeutic options are limited and often ineffective. The paper highlights that cancer stem-like cells (CSCs) are believed to be the root of metastasis, making them a critical target for developing new anti-metastatic therapies. Salinomycin, previously identified as a selective inhibitor of CSCs in various cancers, presents a promising candidate for tackling UM metastasis, but its efficacy and underlying mechanisms in UM needed to be explored.

Methods

The researchers employed a multi-pronged approach to evaluate salinomycin's efficacy:

  • In vitro studies:
    • Cell Viability and Colony-Formation Assays: Standard MTS assays were used to measure cell viability, and a double-layer agarose system assessed the colony-forming capacity of UM cells after salinomycin treatment.
  • Apoptosis Assays: Annexin V-FITC/PI staining and flow cytometry were used to quantify apoptosis. Western blot analysis was employed to detect the cleavage of PARP and activation of caspase-3, key markers of apoptosis. Mitochondrial membrane potential (ΔΨm) was also assessed using MitoTracker probes.
  • Melanosphere Formation and Aldehyde Dehydrogenase (ALDH) Assay: These assays are standard for evaluating CSC self-renewal and stemness, respectively.
  • Transwell Migration and Invasion Assays: These assays, including wound healing scratch tests and Matrigel-coated transwell chambers, were used to assess the ability of UM cells to migrate and invade.
  • Gene Manipulation: Lentiviral constructs were used to overexpress or silence key genes (Survivin, Twist1) to understand their role in salinomycin's effects.
  • In vivo studies:
    • Xenograft Models: NOD/SCID mice were injected with UM cells to create subcutaneous tumors. Salinomycin treatment was administered to assess its impact on tumor growth and weight. Immunohistochemistry (IHC) was used to analyze proliferation (Ki67) and apoptosis (active caspase-3) in tumor tissues.
  • Hepatic Metastasis Model: NOG mice were injected with UM cells into the spleen to mimic liver metastasis. In vivo bioluminescence imaging and macroscopic examination of the liver were used to quantify metastatic burden.

Datasets

Not discussed in the paper.

Key Insights and Ideas

  • Salinomycin as a dual-action agent: The study reveals salinomycin's ability to not only inhibit tumor cell growth but also specifically target CSCs, which are notoriously resistant to conventional therapies.
  • Survivin's protective role: The research identified Survivin as a key protein that confers resistance to salinomycin-induced apoptosis. Overexpressing Survivin protected UM cells from salinomycin, while knocking it down sensitized them.
  • Twist1 as a critical mediator: Twist1 emerged as a crucial transcription factor in salinomycin's mechanism of action. Salinomycin reduced Twist1 levels, and manipulating Twist1 expression (either overexpressing or silencing) directly impacted CSC phenotypes, migration, and invasion.
  • Clinical relevance of Twist1: The study found that high Twist1 expression in UM patients correlated with poorer survival outcomes, suggesting Twist1 as a potential therapeutic target.
  • Safety profile: Salinomycin showed significantly lower toxicity in normal retinal cells compared to UM cells, hinting at a potentially favorable therapeutic window.

Key Results

  • Salinomycin effectively inhibited the viability and colony-forming capacity of UM cell lines in vitro, with IC50 values in the low micromolar range.
  • Salinomycin induced apoptosis in UM cells in a dose- and time-dependent manner, evidenced by PARP cleavage, caspase-3 activation, and cytochrome c release.
  • In vivo, salinomycin significantly suppressed tumor growth and weight in xenograft models.
  • Salinomycin treatment markedly reduced cell migration and invasion in vitro.
  • In a hepatic metastasis model, salinomycin significantly reduced bioluminescence signals and the number of metastatic nodules in the liver.
  • Salinomycin significantly reduced the number and size of melanospheres (a marker of CSC self-renewal) and decreased ALDH-positive cells (another CSC marker).
  • Salinomycin treatment led to decreased protein levels of Twist1 and SOX2 in UM cells.
  • Overexpression of Survivin partially rescued UM cells from salinomycin-induced apoptosis, while Survivin knockdown enhanced it.
  • Forced expression of Twist1 attenuated the effects of salinomycin on CSC phenotypes, while Twist1 knockdown potentiated salinomycin's inhibitory effects.

Limitations and Future Work

  • Twist1's partial role: While Twist1 is shown to be fundamental, the authors acknowledge that other regulators likely contribute to salinomycin's effects on CSCs, as Twist1 only partially reversed salinomycin's impact.
  • SOX2's potential role: The study noted that salinomycin reduced SOX2 protein levels, a known stemness regulator, but high SOX2 expression wasn't directly correlated with metastasis-free survival in the analyzed datasets. Further investigation into SOX2's role is warranted.
  • Clinical translation: The findings provide preclinical evidence, and the authors suggest that further testing of salinomycin in clinical trials for UM patients with hepatic metastasis is warranted.
  • Other cancer types: The authors suggest that exploring salinomycin's efficacy and mechanisms in other cancer types could be beneficial.

Summary updated

Abstract

Our findings suggest that targeting UM CSCs by salinomycin is a promising therapeutic strategy to hamper hepatic metastasis in UM. These results provide the first pre-clinical evidence for further testing of salinomycin for its antitumor efficacy in UM patients with hepatic metastasis.
BibTeX
@inproceedings{zhou2019salinomycin,
  author = {Jingfeng Zhou and Shenglan Liu and Yun Wang and Wei Dai and Hailin Zou and Shubo Wang and Jing Zhang and Jingxuan Pan},
  title = {{Salinomycin effectively eliminates cancer stem-like cells and obviates hepatic metastasis in uveal melanoma}},
  booktitle = {Molecular},
  year = {2019},
  doi = {10.1186/s12943-019-1068-1},
}
Figure